{"id":"NCT03804268","sponsor":"Allergan","briefTitle":"Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia","officialTitle":"A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants With Presbyopia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-21","primaryCompletion":"2019-10-31","completion":"2019-10-31","firstPosted":"2019-01-15","resultsPosted":"2021-12-28","lastUpdate":"2021-12-28"},"enrollment":323,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Presbyopia"],"interventions":[{"type":"OTHER","name":"Vehicle","otherNames":[]},{"type":"DRUG","name":"Pilocarpine HCl Ophthalmic Solution","otherNames":["AGN-190584","VUITY"]}],"arms":[{"label":"Vehicle","type":"PLACEBO_COMPARATOR"},{"label":"Pilocarpine HCl Ophthalmic Solution","type":"EXPERIMENTAL"}],"summary":"A study to evaluate the efficacy, safety, and pharmacokinetics of pilocarpine hydrochloride (HCl) ophthalmic solution (AGN-190584) when administered bilaterally, once daily for 30 days in participants with presbyopia.","primaryOutcome":{"measure":"Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 3","timeFrame":"Baseline (Day 1) to Day 30 (Hour 3)","effectByArm":[{"arm":"Vehicle","deltaMin":8.1,"sd":null},{"arm":"Pilocarpine HCl Ophthalmic Solution","deltaMin":30.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":6},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":["37702453","35848990","35238902"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":159},"commonTop":["Headache"]}}